Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eye drop and preparation method thereof

An eye drop and solution technology, applied in pharmaceutical formulations, medical preparations containing active ingredients, peptide/protein components, etc., can solve the problem of no anti-inflammatory and anti-lymphatic effects, unclear relationship between corneal diseases, and affecting the ocular surface of patients. Micro-environment and other issues, to facilitate the work of clinicians, reduce the occurrence of complications and sequelae, and reduce adverse reactions

Active Publication Date: 2010-09-15
XIAMEN UNIV
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the function of Netrin family in normal cornea and inflammatory tissue has not yet been studied, and the mechanism is poorly understood. The attention of many ophthalmologists
[0004] At present, there are no anti-inflammatory, anti-neovascular and anti-lymphatic eye drops products on the market. Most ophthalmic drugs used in clinical practice have limited therapeutic functions, and there may be interactions and constraints among various drug components. Factors, plus the toxic ingredients and preservatives in various combined eye drops will damage the ocular surface microenvironment, make the existing ocular surface diseases worse, and bring certain confusion to the treatment of various corneal diseases; in addition , most anti-inflammatory products contain hormone ingredients, long-term use can seriously affect the ocular surface microenvironment of patients, some anti-inflammatory drugs have related complications such as large doses of chloramphenicol eye drops can cause eyelid and corneal edema , eye movement restriction and optic disc atrophy, long-term application can cause aplastic anemia, etc.; anti-neovascular drugs, such as artesunate (Chen Huanhuan, Zhou Huijun. Antiangiogenic effect of artesunate. Acta Pharmaceutica Sinica 2004, 39 (1): 29-33) eye drops, the composition is relatively complex, the effect is not sure enough, and it has no anti-inflammatory and anti-lymphatic effect; doxycycline eye drops is an effective drug for treating inflammation, but there is no official drug in my country at present. commercial formulation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eye drop and preparation method thereof
  • Eye drop and preparation method thereof
  • Eye drop and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Based on 10ml of eye drops, 7.4ml of PBS is used as the base solution, containing 200μl of fetal bovine serum, 100μl of low-molecular dextran, 200μl of HEPES, 100μl of tobramycin, 2ml of recombinant Netrin4 protein, the pH value is 7.2-7.4, and the osmotic pressure is 350 ~380mOsm / L.

[0044] Preparation method 1: Dissolve 50 μg of recombinant Netrin4 protein and 100 μg of low-molecular dextran in 2 ml of PBS solution, then mix with 200 μl of fetal bovine serum, 200 μl of 1M HEPES and 100 μl of 10% tobramycin, add PBS solution to 10ml, and adjust the pH value 7.2 to 7.4, osmotic pressure of 350 to 380mOsm / L, filtered through a 0.2μm membrane to obtain Netrin4 eye drops.

[0045] Preparation method 2: Make 50 μg of Netrin4 into sterile micropowder, add 100 μg of low-molecular dextran, 200 μl of fetal bovine serum, 200 μl of 1M HEPES, 100 μl of 10% tobramycin and 9.4 ml of PBS, adjust the pH value to 7.2-7.4, and pass through 0.2 μm Sterilize by membrane filtration, and ...

Embodiment 2

[0047] Based on 10ml of eye drops, 7.4ml of HBSS as the base solution, containing 200μl of fetal bovine serum, 100μl of low-molecular dextran, 200μl of HEPES, 100μl of tobramycin, 2ml of recombinant Netrin4 protein, pH value of 7.2-7.4, osmotic pressure of 350 ~380mOsm / L.

[0048] Preparation method 1: Dissolve 50 μg recombinant Netrin4 protein and 100 μg low-molecular-weight dextran in 2ml HBSS solution, then mix with 200 μl fetal bovine serum, 1M HEPES 200 μl and 10% tobramycin 100 μl, add HBSS solution to 10 ml, and adjust the pH value 7.2 to 7.4, osmotic pressure of 350 to 380mOsm / L, filtered through a 0.2μm membrane to obtain Netrin4 eye drops.

[0049] Preparation method 2: Make 50 μg of Netrin4 into sterile micropowder, add 100 μg of low-molecular dextran, 200 μl of fetal bovine serum, 200 μl of 1M HEPES, 100 μl of 10% tobramycin and 9.4 ml of HBSS, adjust the pH value to 7.2-7.4, and pass through 0.2 μm Sterilize by membrane filtration, and then dissolve the Netrin4 p...

Embodiment 3

[0051] Based on 10ml of eye drops, 7.4ml of normal saline is used as the basic solution, containing 200μl of fetal bovine serum, 100μl of low-molecular dextran, 200μl of HEPES, 100μl of tobramycin, 2ml of recombinant Netrin4 protein, the pH value is 7.2-7.4, and the osmotic pressure is 350~380mOsm / L.

[0052] Preparation method 1: Dissolve 50 μg of recombinant Netrin4 protein and 100 μg of low-molecular-weight dextran in 2 ml of normal saline solution, then mix well with 200 μl of fetal bovine serum, 200 μl of 1M HEPES and 100 μl of 10% tobramycin, add normal saline solution to 10 ml, Adjust the pH value to 7.2-7.4, the osmotic pressure to 350-380mOsm / L, filter and sterilize through a 0.2μm membrane to obtain Netrin4 eye drops.

[0053] Preparation method 2: 50 μg of Netrin4 was made into sterile micropowder, 100 μg of low-molecular dextran, 200 μl of fetal bovine serum, 200 μl of 1M HEPES, 100 μl of 10% tobramycin and 9.4 ml of normal saline were adjusted to a pH value of 7.2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an eye drop and a preparation method thereof, relating to an eye drop. The invention provides an eye drop with short action time, high purity and relatively good effect and capability of simultaneously playing a role of corneal neovascularization, lymphangiogenesis and cornea inflammation resistance and a preparation method thereof. The eye drop contains the following components by volume percent: 0.1-5% of bovine serum, 5-15% of thickening agent, 1-5% of acid-base regulating solution, 0.5-2% of antibiotics, 5-20% of recombinant protein and the balance of balanced salt solution. The eye drop contains the balanced salt solution, the thickening agent, the bovine serum, the antibiotics, the acid-base regulating solution and the recombinant protein. The preparation method of the eye drop comprises the following steps of: adding the thickening agent, the bovine serum, the antibiotics and the recombinant protein to the balanced salt solution, regulating a pH value by using the acid-base regulating solution and osmotic pressure by using an osmotic pressure buffering agent, and removing bacteria through membrane filtration; or preparing the bovine serum to sterile micropowder, dissolving the bovine serum into the balanced salt solution, regulating the pH value, removing the bacteria through the membrane filtration, and dissolving recombined powder into the solution so as to obtain the eye drop.

Description

technical field [0001] The invention relates to an eye drop, in particular to an eye drop for treating corneal neovascularization, neolymphatic vessel and corneal inflammatory diseases and a preparation method thereof. Background technique [0002] According to the report of the World Health Organization, corneal disease is the second major cause of vision loss. Every year, 1.5 to 2 million new corneal blindness are caused by corneal ulcers and ocular trauma, which seriously threatens the health of patients. In corneal diseases, the most important cause of blindness is corneal vascularization and scarring, and the limitation of therapeutic drugs is also a key issue. Corneal new blood vessels and new lymphatic vessels can be secondary to a variety of corneal inflammatory diseases (keratitis, ulcers, etc.) The pathological reaction of corneal transplantation may lead to rejection and inflammation during corneal transplantation, seriously affecting the vision recovery of patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K38/19A61K47/42A61P27/02
Inventor 刘祖国邵毅韩云李炜瞿杨洛娃
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com